- Home
- RMMZ vs COYA Comparison
RMMZ vs COYA Comparison
Compare RMMZ & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- COYA
- Stock Information
- Founded
- RMMZ 2022
- COYA 2020
- Country
- RMMZ United States
- COYA United States
- Employees
- RMMZ N/A
- COYA N/A
- Industry
- RMMZ Investment Managers
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- COYA Health Care
- Exchange
- RMMZ Nasdaq
- COYA Nasdaq
- Market Cap
- RMMZ 122.3M
- COYA 107.0M
- IPO Year
- RMMZ N/A
- COYA 2022
- Fundamental
- Price
- RMMZ $14.94
- COYA $5.73
- Analyst Decision
- RMMZ
- COYA Strong Buy
- Analyst Count
- RMMZ 0
- COYA 4
- Target Price
- RMMZ N/A
- COYA $16.50
- AVG Volume (30 Days)
- RMMZ 25.6K
- COYA 116.6K
- Earning Date
- RMMZ 01-01-0001
- COYA 11-05-2025
- Dividend Yield
- RMMZ 7.33%
- COYA N/A
- EPS Growth
- RMMZ N/A
- COYA N/A
- EPS
- RMMZ 0.82
- COYA N/A
- Revenue
- RMMZ N/A
- COYA $423,452.00
- Revenue This Year
- RMMZ N/A
- COYA $40.80
- Revenue Next Year
- RMMZ N/A
- COYA N/A
- P/E Ratio
- RMMZ $19.41
- COYA N/A
- Revenue Growth
- RMMZ N/A
- COYA N/A
- 52 Week Low
- RMMZ $12.92
- COYA $4.65
- 52 Week High
- RMMZ $16.99
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- RMMZ 63.32
- COYA 41.59
- Support Level
- RMMZ $14.85
- COYA $5.37
- Resistance Level
- RMMZ $14.87
- COYA $6.53
- Average True Range (ATR)
- RMMZ 0.18
- COYA 0.43
- MACD
- RMMZ 0.01
- COYA -0.11
- Stochastic Oscillator
- RMMZ 70.71
- COYA 23.84
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.